Celltrion launches antigen and serology COVID-19 tests in the U.S., Verily adds capacity with CLIA lab and more

COVID-19 diagnostic developments this week include the addition of two types of COVID-19 rapid test kits by Celltrion and Verily’s move to boost capacity with a new CLIA lab in South San Francisco. 

Celltrion Inc. (KSE:068270) is planning to launch antigen- and antibody-detecting test kits by next week; both are under FDA review for emergency use authorization (EUA). The antigen test, SAMPINUTE COVID-19 Antigen MIA, uses mAbs to detect the SARS-CoV-2 spike protein in nasopharyngeal swabs. The company said its has a 94% sensitivity and a 100% specificity; and can give results in 10 minutes...